title: Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
abstract: BACKGROUND
  This double blind parallel group study assessed the acute antiemetic efficacy of four oral doses of dolasetron mesylate in cancer patients receiving their first course of intravenous chemotherapy with doxorubicin and/or cyclophosphamide.
  
  
  METHODS
  Patients were randomized to receive 25, 50, 100, or 200 mg of dolasetron mesylate 30 minutes prior to chemotherapy and were monitored for nausea and emetic episodes for the next 24 hours.
  
  
  RESULTS
  Three hundred and nineteen cancer patients at 32 sites completed the study. Most patients were female (81%); of this group, 69% had breast carcinoma. A highly statistically significant linear trend demonstrating improved response with higher doses was detected for complete response (no emetic episodes and no rescue medication) (P < 0.001), for complete plus major response (0-2 emetic episodes and no rescue medication) (P < 0.001), and for patient visual analog scale assessments of nausea (P = 0.001) and general satisfaction with antiemetic therapy (P = 0.001). No serious adverse events were noted. The most frequent adverse event was mild, self-limiting headache, which has been reported with other drugs in this class.
  
  
  CONCLUSIONS
  Single oral doses of dolasetron mesylate were found to be effective in preventing acute emesis in cancer patients receiving moderately emetogenic chemotherapy.
authors.affiliation: M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: E B
authors.initials: EB
authors.lastname: Rubenstein
authors.forename: R J
authors.initials: RJ
authors.lastname: Gralla
authors.forename: J D
authors.initials: JD
authors.lastname: Hainsworth
authors.forename: P J
authors.initials: PJ
authors.lastname: Hesketh
authors.forename: T H
authors.initials: TH
authors.lastname: Grote
authors.forename: M R
authors.initials: MR
authors.lastname: Modiano
authors.forename: A
authors.initials: A
authors.lastname: Khojasteh
authors.forename: L A
authors.initials: LA
authors.lastname: Kalman
authors.forename: C R
authors.initials: CR
authors.lastname: Benedict
authors.forename: W F
authors.initials: WF
authors.lastname: Hahne
mesh_terms: D000284:Administration, Oral; D000932:Antiemetics / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D011807:Quinolizines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D007211:Indoles; D011807:Quinolizines; D004317:Doxorubicin; C060344:dolasetron; D003520:Cyclophosphamide